Country: Canada
Language: English
Source: Health Canada
MEROPENEM (MEROPENEM TRIHYDRATE)
SUN PHARMA CANADA INC
J01DH02
MEROPENEM
500MG
POWDER FOR SOLUTION
MEROPENEM (MEROPENEM TRIHYDRATE) 500MG
INTRAVENOUS
15G/50G
Prescription
CARBAPENEMS
Active ingredient group (AIG) number: 0128599001; AHFS:
APPROVED
2020-12-22
_Pr_ _TARO-MEROPENEM (Meropenem For Injection USP, 500 mg, 1 g per vial) Product Monograph _ Page 1 of 36 PRODUCT MONOGRAPH PR TARO-MEROPENEM Meropenem For Injection USP, 500 mg, 1 g per vial (as meropenem trihydrate) For intravenous use Antibiotic Sun Pharma Canada Inc. 126 East Drive Brampton, ON L6T 1C1 Date of Revision: December 18, 2020 Submission Control No: 243010 _Pr_ _TARO-MEROPENEM (Meropenem For Injection USP, 500 mg, 1 g per vial) Product Monograph _ Page 2 of 36 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ................................................................. 3 SUMMARY PRODUCT INFORMATION ................................................................................. 3 INDICATIONS AND CLINICAL USE ...................................................................................... 3 CONTRAINDICATIONS ............................................................................................................ 5 WARNINGS AND PRECAUTIONS .......................................................................................... 5 ADVERSE REACTIONS ............................................................................................................ 8 DRUG INTERACTIONS ........................................................................................................... 11 DOSAGE AND ADMINISTRATION ....................................................................................... 11 OVERDOSAGE ......................................................................................................................... 15 ACTION AND CLINICAL PHARMACOLOGY ..................................................................... 15 STORAGE AND STABILITY .................................................................................................. 21 DOSAGE FORMS, COMPOSITION AND PACKAGING ...................................................... 22 PART II: SCIENTIFIC INFORMATION ...................................................................................... 23 PHAR Read the complete document